Sanofi-Aventis Healthcare - Nature's Own Glucosamine Sulfate & Bio-Organic Glucosamine

Therapeutic Goods Act 1989

Approval under section 42DF for use of restricted representations by Sanofi-Aventis Healthcare Pty Ltd

I, Simon Waters, Delegate of the Secretary to the Department of Health, on receipt of an application from Sanofi-Aventis Healthcare Pty Ltd t/a Sanofi Consumer Healthcare, have approved under section 42DF of the Therapeutic Goods Act 1989 (the Act) the restricted representations described in paragraphs (a) and (b) below for use in advertisements directed to consumers, for the products identified in paragraph (c), provided the condition identified in paragraph (d) is met:

1. Representations that refer to 'arthritis', 'osteoarthritis', and 'rheumatoid arthritis' to the effect of providing accurate, balanced and contemporary information, the purpose of which is to inform consumers that there are different types of arthritis and to describe their key features.
2. Representations that refer to "osteoarthritis" to the effect that the products identified in paragraph (c):
   • may relieve joint pain caused by osteoarthritis;
   • may help increase joint mobility associated with  osteoarthritis; and
   • to the effect that long term supplementation may protect joint cartilage in osteoarthritis.
3.  
   • Nature's Own Glucosamine Sulfate 1500 (AUST L 285404)
   • Nature's Own Glucosamine Sulfate 1500 with Chondroitin (AUST L 285459)
   • Nature's Own Glucosamine Sulfate & Chondroitin Advanced (AUST L 285684)
   • Bio-Organic Glucosamine 750 + Chondroitin 400 Complex (AUST L 286023)
   • Bio-Organic Glucosamine Sulfate Advanced (AUST L 286071)
4. Information about the different types of arthritis must merely distinguish the types of arthritis and their key features. This must be both the purpose of the information and its likely consequence. That is, any information about the different types of arthritis must in no way state or imply that the medicines being advertised are being promoted for any condition other than osteoarthritis.

Dated this 19th day of September 2017

Simon Waters
Delegate of the Secretary to the Department of Health
Advertising Compliance Unit
Regulatory Practice, Education and Compliance Branch